All In Biotech

Drug Trial Radar · NCT07644195

Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers

A Phase 1, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Inhaled TRL1068 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

14

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Trellis Bioscience LLCIndustry
Sponsor type
Industry
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Jun 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study in healthy volunteers will provide a basis for evaluation of inhaled TRL1068 as a first in human study, specifically, important safety, tolerability, and pharmacokinetic data.

Conditions

  • Healthy Volunteer

Interventions

  • TRL1068, a human monoclonal antibodyDrug

    The IP will be in a solution for inhalation at a nominal concentration of 20 mg/mL. The IP will be reconstituted with a formulation buffer to 10 mg/mL/PS20 0.055% and dosed at a fixed dose of 60 mg per dose (volume of 6 mL) to full completion. Placebo will be normal saline. This study will use a marketed nebulizer device, the Aerogen Solo™, which is designed to generate an aerosol to achieve effective levels of TRL1068 in distal airways.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of abnormal physical exam findingsTime frame: 30 days
  2. Severity of abnormal physical exam findingsTime frame: 30 days
  3. Incidence of abnormal serum chemistries and hematologyTime frame: 30 days
  4. Severity of abnormal serum chemistries and hematologyTime frame: 30 days
  5. Incidence of abnormal vital signs (temperature)Time frame: 30 days
  6. Severity of abnormal vital signs (temperature)Time frame: 30 days
  7. Incidence of abnormal vital signs (blood pressure)Time frame: 30 days
  8. Severity of abnormal vital signs (blood pressure)Time frame: 30 days
  9. Incidence of abnormal vital signs (heart rate)Time frame: 30 days
  10. Severity of abnormal vital signs (heart rate)Time frame: 30 days
  11. Incidence and Severity of Adverse EventsTime frame: 30 days
  12. Incidence of Serious Adverse EventsTime frame: 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.